Atea Pharmaceuticals (AVIR) Return on Sales (2021 - 2022)
Atea Pharmaceuticals has reported Return on Sales over the past 2 years, most recently at 0.19% for Q3 2022.
- Quarterly results put Return on Sales at 0.19% for Q3 2022, up 104.0% from a year ago — trailing twelve months through Sep 2022 was 0.19% (up 3.0% YoY), and the annual figure for FY2021 was 0.34%, up 57.0%.
- Return on Sales for Q3 2022 was 0.19% at Atea Pharmaceuticals, up from 0.07% in the prior quarter.
- Over the last five years, Return on Sales for AVIR hit a ceiling of 0.61% in Q4 2021 and a floor of 0.86% in Q3 2021.